RxDoctor Payments Data

Jorge Ramallo, MD

Internal Medicine · Alexandria, VANPI 1215354360

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,858 of the $34,149 with a category attached, or 81.6%. Gilead accounts for 99.8% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $33,865, more than ten times the $163 reported in 2019. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,149in general payments, 2019–2025

Across 48 payments — averaging $711.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$34K
  • Johnson & Johnson$28
  • Viiv Healthcare Company$18
  • Merck$16

What the payments were for

  • Speaking & faculty fees$27,85882%
  • Travel & lodging$5,34216%
  • Food & beverage$9503%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead45$34,088
Johnson & Johnson1$28
Viiv Healthcare Company1$18
Merck1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,149 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$9,463
Medicare patients
19
Services billed
2,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala34$161,266
DovatoDolutegravir Sodium/Lamivudine12$35,144
OzempicSemaglutide14$21,720
Testosterone Cypionate12$1,173
Bupropion XlBupropion Hcl13$817
Ezetimibe12$199
Atorvastatin Calcium25$186
Levothyroxine Sodium18$164
Metoprolol Succinate18$64
Rosuvastatin Calcium14$55
Amlodipine Besylate11$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$34,088$161,26634 claims
Viiv Healthcare CompanyDovato$18$35,14412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →